Share on StockTwits
 

Investment analysts at Maxim Group initiated coverage on shares of Quest Diagnostics (NYSE:DGX) in a note issued to investors on Tuesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $68.00 price target on the stock. Maxim Group’s price target would suggest a potential upside of 27.44% from the company’s current price.

Shares of Quest Diagnostics (NYSE:DGX) traded down 0.74% on Tuesday, hitting $53.36. 3,703,185 shares of the company’s stock traded hands. Quest Diagnostics has a 52 week low of $51.90 and a 52 week high of $64.10. The stock has a 50-day moving average of $54.21 and a 200-day moving average of $58.84. The company has a market cap of $7.760 billion and a price-to-earnings ratio of 11.03.

A number of other firms have also recently commented on DGX. Analysts at FBR Capital Markets cut their price target on shares of Quest Diagnostics from $68.00 to $60.00 in a research note to investors on Monday. They now have a “market perform” rating on the stock. Separately, analysts at JMP Securities initiated coverage on shares of Quest Diagnostics in a research note to investors on Wednesday, December 18th. They set a “market perform” rating on the stock. Finally, analysts at Morgan Stanley reiterated an “underweight” rating on shares of Quest Diagnostics in a research note to investors on Thursday, December 12th. They now have a $58.00 price target on the stock. Five investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating to the stock. Quest Diagnostics presently has an average rating of “Hold” and an average price target of $58.89.

Quest Diagnostics Incorporated (NYSE:DGX)is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.